Patent · US Active

Kinase inhibitors

US8455656B2 · kind B2 · utility

2Cited by

112References

2Claims

0Family size

Assignee

Allergan, Inc. · US

Inventors

Lon T. Spada · Walnut, US
Jane-Guo Shiah · Irvine, US
Patrick M. Hughes · Aliso Viejo, US
Thomas C. Malone · Irvine, US
Gerald W. DeVries · San Clemente, US
Jeffrey L. Edelman · Irvine, US
Julie A. Wurster · Irvine, US
Xialing Guo · San Clemente, US
Sougato Boral · Irvine, US

Key dates

Filing date	Feb 26, 2009
Grant date	Jun 4, 2013
Priority date	—
Expiry date	Feb 26, 2029

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/5031
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.